Zacks Investment Research upgraded shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a sell rating to a hold rating in a report published on Monday.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

Several other equities research analysts have also issued reports on APTO. ValuEngine lowered shares of Aptose Biosciences from a sell rating to a strong sell rating in a research note on Friday, September 1st. HC Wainwright upgraded shares of Aptose Biosciences from a neutral rating to a buy rating and raised their price target for the stock from $1.00 to $4.00 in a research note on Thursday, September 7th. Roth Capital restated a buy rating and set a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $7.00 price target on shares of Aptose Biosciences and gave the stock a buy rating in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $5.00.

Shares of Aptose Biosciences (NASDAQ:APTO) opened at $2.25 on Monday. Aptose Biosciences has a one year low of $0.78 and a one year high of $2.58. The stock has a market cap of $41.73, a P/E ratio of -3.46 and a beta of 2.57.

ILLEGAL ACTIVITY WARNING: “Aptose Biosciences (APTO) Upgraded to Hold by Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/aptose-biosciences-apto-upgraded-to-hold-by-zacks-investment-research/1786776.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.